Amyloid-based therapeutics: Findings translated into novel treatments

CNS Spectrums

Volumn 13, Issue 10 SUPPL. 16, 2008, Pages 36-38

  Aisen, Paul S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA SECRETASE; ALPHA TOCOPHEROL; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; AMYLOID PROTEIN; ANTIINFLAMMATORY AGENT; BETA SECRETASE; BETA SECRETASE INHIBITOR; CHOLINESTERASE INHIBITOR; DOCOSAHEXAENOIC ACID; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; HOMOTAURINE; IMMUNOGLOBULIN; INOSITOL; MEMANTINE; MONOCLONAL ANTIBODY; NEUROTROPHIC FACTOR; PRESENILIN 1; PRESENILIN 2; TACRINE; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; BRAIN MITOCHONDRION; CLINICAL TRIAL; COGNITIVE DEFECT; DIET SUPPLEMENTATION; DOWN SYNDROME; DRUG EFFICACY; DRUG TARGETING; ENZYME INHIBITION; GENE MUTATION; HEREDITY; HUMAN; IMMUNOTHERAPY; NEUROBIOLOGY; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SENILE PLAQUE; UNSPECIFIED SIDE EFFECT; VACCINATION;

EID: 56249113825     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s109285290002705x     Document Type: Article

References (15)

1. Summers WK, Majovski LV, Marsh GM. Tachiki K, Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, alzheimer type. N Engl J Med. 1986;315:1241-1245.
2. Cummings JL Alzheimer's disease. N Engl J Med. 2004;351:56-67
3. Miller ER, 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: High-dosage age vitamin e supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37-46.
4. Lonn E, Bosch J, Yusuf S, et al. Effects of long-term vitamin e supplementation on cardiovascular events and cancer. A randomized controlled trial. JAMA. 2005;293:1338-1347.
5. Petersen RC, Thomas RG, Grundman M, et al. Vitamin e and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352(23):2379-2388.
6. Aisen PS. Treatment for mci: Is the evidence sufficient? Neurology. 2008;70:2020-2021.
7. Aisen PS. The development of anti-amyloid therapy for alzheimer's disease: From secretase modulators to polymerisation inhibitors. CNS Drugs. 2005;19:989-996
8. Hardy J, Selkoe DJ. The amyloid hypothesis of alzheimer's disease: Progress and problems on the road to therapeutics. Science. 2002;297:353-356.
9. Fox NC. Black RS. Gilman S, et al. Effects of abete immunization (an1792) on mri measures at cerebral volume in alzheimer disease. Neurology. 2005;64:1563-1572.
10. Gilman S. Koller M, Black RS, et al. Clinical effects of abate immunization (an1792) in patients with ad in an interrupted trial. Neurology. 2005;64:1553-1562.
11. Aisen PS, Saumier D, Briand R, et al. A phase ii study targeting amyloid-beta with 3aps in mild-to-moderate alzheimer disease. Neurology. 2006;67:1757-1763
12. McLaurin J, Kierstead ME, Brown ME, et al. Cyclohexanehaxol inhibitors of abeta aggregation prevent and reverse alzheimer phenotype in a mouse model. Nat Med. 2006;12:801-808.
13. Sano M. Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for alzheimer's disease. N Engl J Med. 1997;336:1216-1222.
14. Tuszynski MH, Thal L, Pay M, et al. A phase 1 clinical trial of nerve growth factor gene therapy for alzheimer disease. Nat Med. 2005;11:551-555.
15. Matsuoka Y, Jouroukhin Y. Gray AJ, et al. A neuronal microtubule-interacting agent, napvsipq, reduces tau pathology and enhances cognitive function in a mouse model of alzheimer's disease. J Pharmacol Exp Ther. 2008;325:146-153.